Virological and drug-resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in six PEPFAR-supported countries: a prospective cohort study
在六个由美国总统艾滋病紧急救援计划（PEPFAR）支持的国家中，艾滋病毒感染者开始或改用替诺福韦、拉米夫定和多替拉韦治疗的病毒学和耐药性结果：一项前瞻性队列研究
期刊:Lancet HIV
影响因子:13
doi:10.1016/S2352-3018(25)00162-6
Marc, Jean Bernard; McCarthy, Caitlyn; Wallis, Carole L; Kityo, Cissy; Hughes, Michael D; Godfrey, Catherine; Shah, N Sarita; Parikh, Urvi M; Maartens, Gary; Kanyike, Francis; Van Schalkwyk, Marije; Kihumuro, Raymond Bernard; Asiimwe, Philip; Tsikhutsu, Isaac; Munyanga, Cornelius; Some, Fatma F; Joseph, Yvetot; Flowers, Tracy; Mohapi, Lerato; Samaneka, Wadzanai P; Mponda, Kelvin; Rassool, Mohammed S; Pierre, Samuel; Woolley, Elizabeth; Manabe, Yukari C; Mellors, John W; Flexner, Charles; Koenig, Serena P; Mngqibisa, Rosie
